toxylact: a02bx02 sucralfate

The first professional lActological database in the word

Sucralfate (ATC A02BX02) is generally considered compatible with breastfeeding, with minimal systemic absorption and only theoretical risk of aluminum accumulation in women with significant renal impairment.

Pharmacological profile

Sucralfate is a basic aluminum salt of sulfated sucrose that acts as a locally active gastro-duodenal mucosal protective agent. It is indicated for short-term treatment of active duodenal ulcer and for maintenance to prevent recurrence, and is also used in gastric ulcer, GERD, gastritis and stress-ulcer prophylaxis. The drug forms a viscous paste in acidic gastric pH that selectively binds to ulcer surfaces, creating a protective barrier against acid and pepsin and promoting healing. Sucralfate is classified in ATC group A02BX02 (alimentary tract and metabolism – other antiulcer agents).

Systemic absorption of sucralfate after oral administration is very low; less than about 5% of the dose is absorbed, and most of the drug (including the aluminum complex) is eliminated unchanged in the feces. The elimination half-life of the small absorbed fraction is reported in the range of roughly 6–20 hours, but this has little clinical relevance in patients with normal renal function due to the low absorbed amount.

Toxicology and adverse effects

Sucralfate is generally well tolerated, with predominantly mild gastrointestinal adverse effects such as constipation, nausea, vomiting, diarrhea, and dry mouth, and occasional minor hypersensitivity reactions. In patients with normal renal function, clinically relevant aluminum accumulation is not expected, given the minimal absorption and predominant fecal excretion.

In patients with compromised renal function (chronic kidney disease or end-stage renal disease), aluminum accumulation and toxicity have been reported with sucralfate therapy, manifesting as osteodystrophy, osteomalacia, and encephalopathy. The toxic risk may be enhanced when sucralfate is combined with agents that increase aluminum absorption (for example, citric acid–containing preparations), and at high cumulative doses or prolonged courses. Therefore, sucralfate should be used with particular caution or avoided in severe renal impairment, and alternative non-aluminum-containing gastroprotective agents may be preferable in this setting.

Other clinical cautions mentioned in product information and expert guidance include use in patients with diabetes (due to sucrose content in some formulations), significant swallowing disorders (risk of aspiration of suspension or tablets), and known hypersensitivity to sucralfate or excipients.

Lactation safety

Most expert sources consider sucralfate acceptable during breastfeeding, and it is generally listed as compatible. Systemic absorption in the mother is minimal, so only trace amounts, if any, would be expected to reach breast milk. Given sucralfate’s poor oral bioavailability and the tiny potential exposure, the breastfed infant is very unlikely to absorb any clinically significant quantity from milk, and even gastrointestinal toxicity is not expected.

Some product monographs state that it is not known whether sucralfate is excreted in human milk and recommend caution when administering the drug to nursing women, reflecting a precautionary labeling approach rather than documented harm. LactMed and other lactation-focused resources nonetheless classify sucralfate as acceptable for use in breastfeeding, and routine interruption of breastfeeding or special timing measures are not required. In the local classification used in your project, sucralfate corresponds to a toxico-lactational category I, i.e. fully suitable for use in lactation.

When assessing risk, special attention should be given to mothers with advanced renal impairment, in whom aluminum accumulation risk is higher; in such cases, overall benefit–risk of sucralfate (not specifically lactational risk) should be reconsidered, and other options may be preferred. For healthy breastfeeding women without significant renal disease, sucralfate can be considered a first-line gastroprotective drug from a toxico-lactological perspective.

Pregnancy considerations

Sucralfate is classified as FDA pregnancy category B in older labeling systems, indicating that animal studies have not demonstrated fetal risk and that controlled human data are limited but reassuring. Clinical experience and reviews suggest sucralfate appears safe in pregnancy, and its predominantly local action with minimal systemic absorption further supports its favorable toxicological profile in pregnant patients.

Practical toxico-lactologic conclusions

From a toxico-lactologic standpoint, sucralfate (A02BX02) is a locally acting gastroprotective agent with negligible maternal systemic exposure and almost no expected transfer to breast milk, making it highly suitable for use during breastfeeding. The main toxicological concern is aluminum accumulation in women with severe renal impairment or in special settings of prolonged high-dose therapy and interacting drugs that increase aluminum absorption, where close monitoring or alternative therapy should be considered. In routine clinical practice, standard-dose sucralfate can be used in nursing mothers without dose adjustment, without timing feeds around doses, and without expected adverse effects in the infant.

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.